We’re proud to share that RegASK has been featured in Healthcare Brew’s latest article, “How tariffs on China could impact US healthcare.” The article explores how new tariffs on Chinese pharmaceutical ingredients could drive up drug prices, limit innovation, and strain public health systems.
RegASK CEO Caroline Schleicher explains the potential downstream effects of these tariffs, warning of increased drug costs, potential shortages, Und reduced R&D investment. Her insights highlight the urgency for regulatory bodies, healthcare providers, and pharmaceutical companies to monitor global policy changes that can significantly disrupt access to critical medications.
🔗 Read the full article here: Healthcare Brew – How tariffs on China could impact US healthcare
For further insights into how policy changes like tariffs are reshaping the pharmaceutical industry, read about RegASK’s feature in Bloomberg.
At RegASK, we’re committed to providing accurate and actionable intelligence to help regulatory teams navigate today’s evolving compliance landscape with confidence.
